Global pharmacologic treatments of type 2 diabetes outlined in new study – DiabetesTimes.co.uk

Substantial differences in real-world use of glucose-lowering medications across the US, Sweden and Israel have been highlighted by a team of researchers.  
A new study has found that the use of glucose-lowering medications among people with type 2 diabetes was substantially lower in the US and Sweden compared to in Israel.
During the research process, the team of academics examined data from the National Health and Nutrition Examination Survey (NHANES) from the US, Stockholm CREAtinine Measurements (SCREAM) from Sweden and Maccabi Healthcare Services from Israel.
They found that among people who took at least one glucose-lowering medication in 2017 to 2018, metformin use was lower in NHANES and SCREAM (74.1 per cent in NHANES, 75.9 per cent in SCREAM, and 92.6 per cent in Maccabi) whereas sulfonylureas use was greater in NHANES (31.5 per cent in NHANES, 16.0 per cent in SCREAM, and 14.9 per cent in Maccabi).
According to the results, the adoption of dipeptidyl peptidase 4 inhibitors and sodium–glucose cotransporter 2 inhibitors (SGLT2i) was slower in NHANES and SCREAM than in Maccabi.
The report states: “History of atherosclerotic cardiovascular disease, heart failure, reduced kidney function, or albuminuria was not consistently associated with greater use of SGLT2i or glucagon-like peptide 1 receptor agonists (GLP1RA) across the three countries.”
To access the entire research study, click here.
Register an account or login to comment
Diabetes UK issues latest guidance on coronavirus
People with diabetes urged to be ‘particularly stringent’ amid COVID-19 pandemic
NHS Drug Tariff approval for FreeStyle Libre System
Updated metformin and B12 guidance published
Criticism over Eatwell Plate amid calls for low carb approach
Type 1 man no longer requires insulin
Man commended for living with diabetes for 80 years
Warning over Lucozade sugar reduction
FreeStyle® Libre 2 includes optional real-time alarms
Novo Nordisk UK launches Ozempic® (semaglutide)
Global pharmacologic treatments of type 2 diabetes outlined in new study
Responses sought for JBDS inpatient diabetes teams survey
New continuous blood glucose monitoring research published in top journal
Diabetes nursing to be showcased at Diabetes Professional Care conference
Luton and Dunstable University Hospital wins national award for diabetes campaign
Food addicts to be given hope by new international study
New members sought to join Diabetes UK’s research steering groups
Community diabetes care explored at the Best Practice Show
Continuous glucose monitoring comparison chart published
Pancreatic image bank expected to help advance diabetes research worldwide
Specialist Podiatrist Diabetes
Specialist Community Diabetes Dietitian
Consultant in Diabetes & Endocrinology
Specialist Diabetes Dietitian
Health System Engagement Manager – South West and South Central
Volunteer Outreach and Partnerships Officer – South West and South Central
Youth Worker – South West and South Central
Diabetic Specialist Nurse
Diabetes Nurse
Clinical Nurse Specialist – Diabetes / Endocrinology

The Diabetes Times © 2022

source